- Schnittman, Samuel R;
- Kolossváry, Márton;
- Beck-Engeser, Gabriele;
- Fitch, Kathleen V;
- Ambayec, Gabrielle C;
- Nance, Robin M;
- Zanni, Markella V;
- Diggs, Marissa;
- Chan, Fay;
- McCallum, Sara;
- Toribio, Mabel;
- Bamford, Laura;
- Fichtenbaum, Carl J;
- Eron, Joseph J;
- Jacobson, Jeffrey M;
- Mayer, Kenneth H;
- Malvestutto, Carlos;
- Bloomfield, Gerald S;
- Moore, Richard D;
- Umbleja, Triin;
- Saag, Michael S;
- Aberg, Judith A;
- Currier, Judith S;
- Delaney, Joseph AC;
- Martin, Jeffrey N;
- Lu, Michael T;
- Douglas, Pamela S;
- Ribaudo, Heather J;
- Crane, Heidi M;
- Hunt, Peter W;
- Grinspoon, Steven K
Plasma vascular endothelial growth factor (VEGF) coreceptor neuropilin-1 (NRP-1) had the largest association with coronary plaque in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) proteomics analysis. With little known about NRP-1 in people with human immunodeficiency virus (PWH), we explored its relation to other proteins in REPRIEVE and validated our findings through a Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) case-cohort study by assessing its relation to host factors and incident cardiovascular disease and cancer. Within REPRIEVE, NRP-1 was associated with proteins involved in angiogenesis, signal transduction, immunoregulation, and cell migration/adhesion. Within CNICS, NRP-1 was associated with key host factors, including older age and male sex. NRP-1 was associated with an increased hazard of multiple cancers but a decreased prostate cancer risk. Finally, NRP-1 was most strongly associated with mortality and type 2 myocardial infarction. These data suggest that NRP-1 is part of a clinically relevant immunoregulatory pathway related to multiple comorbidities in PWH. Clinical Trials Registration. NCT02344290.